



Resolution n°12-2020-e

Cost Extension for the Project ‘Accelerating Patient Access to Optimal Antiretrovirals and Relevant Health Products’

Recalling Unitaid Executive Board Resolution 6-2016-e of 30 August 2016, in which the Board approved the commitment of up to US\$34,116,827 for the Project entitled “Accelerating Patient Access to Optimal Antiretrovirals” and later renamed ‘Accelerating Patient Access to Optimal Antiretrovirals and Relevant Health Products’ (the “Project”, to be implemented by the Clinton Health Access Initiative (CHAI) for a three-year period;

Recalling Unitaid Executive Board Resolution R22-2018-e of 29 December 2018, in which the Board approved additional funding of up to US\$20,075,828 for the inclusion of Advanced HIV Disease (“AHD”) activities within the Project, and extended the period of funding for the Project by 16 months to 31 December 2020;

Noting the strategic and technical rationale for a further increase to the funding available to the Project in order to maximize its impact, deliver on remaining priorities in HIV treatment optimization and AHD, and extend the reach of paediatric treatment optimization efforts; and

Taking into consideration the COVID-19 pandemic and the need to leverage the mechanisms and structures developed through the Project to support business continuity in national HIV programs, while supporting the COVID-19 response in general;

The Board authorizes, subject to availability of funds, the Executive Director to extend the duration of funding for the Project by 24 months to 31 December 2022 and commit additional funding of up to US\$16,700,000 for the Project.

The additional funding and extension to the Project duration is conditional upon signature of formal amendment to the grant agreement for the Project.

Marisol Touraine
Chair of the Unitaid Executive Board

Date: 7 September 2020